non-small cell lung cancer non-small cell lung cancer
Conditions
Interventions
Stereotactic body radiation therapy using Cyberknife, 18 Gy once a day, total dose 54 Gy, 3 times in total, total treatment period 3-5 days. The acceptable total treatment duration is 10 days. Treatme
Sponsors
Onishi Hiroshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Those diagnosed with non-small cell lung cancer (2)Those diagnosed with c-Stage1 (3)Those who do not have intrathoracic lesions judged to be highly likely to be cancer other than the primary tumor (4)Aged >=18 years, ==2,000 mm3 2 Hb>=8.0 g dl 3 PLT>=3.0 104 mm3 4 T-bil==90 (10)Those who meet the test values below 1 FEV1.0>=700ml (11)Those who have obtained written consent from the patient
Exclusion criteria
Exclusion criteria: (1)Those with active double cancer (2)Those with large cell neuroendocrine carcinoma. (3)Those with infections requiring systemic treatment (4)Those who have a fever of 38degrees Celsius or higher at the time of registration (5)Those with findings of interstitial pneumonia with a clear UIP pattern on CT (6)Those with a cough requiring narcotic drugs (7)Those who have psychosis and are judged to be difficult to participate in research. (8)Pregnant women, lactating women, women who may be pregnant, or those who do not intend to use contraception (9)Those who are judged inappropriate for inclusion in the study by a doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year local progression-free rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, progression-free survival, local progression-free survival, type of progression, early adverse event rate, late adverse event rate, serious adverse event rate, medical device failure | — |
Contacts
Public ContactTakafumi Komiyama
University of Yamanashi Hospital
Outcome results
None listed